Impaired nocifensive behaviours and mechanical hyperalgesia, but enhanced thermal allodynia in pituitary adenylate cyclase-activating polypeptide deficient mice

Neuropeptides

Volumn 44, Issue 5, 2010, Pages 363-371

  Sandor K ^a   Kormos, V ^a   Botz, B ^a   Imreh, A ^a   Bolcskei K ^a   Gaszner, B ^a   Markovics, A ^a   Szolcsanyi J ^a   Shintani, N ^b   Hashimoto, H ^b   Baba, A ^b   Reglodi, D ^a   Helyes, Z ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

C Fos immunohistochemistry; Formalin test; Mechanical hyperalgesia; Neuropathy; Resiniferatoxin; Thermal allodynia; Writhing test

Indexed keywords

ACETIC ACID; FORMALDEHYDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; PROTEIN C FOS; RESINIFERATOXIN; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE POTENTIAL; NEUROPATHIC PAIN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; SCIATIC NERVE; SMOOTH MUSCLE CONTRACTION; SOMATOSENSORY CORTEX; STATISTICAL SIGNIFICANCE; VISCERAL PAIN;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; HOT TEMPERATURE; HYPERALGESIA; IMMUNOHISTOCHEMISTRY; MICE; MICE, KNOCKOUT; NEURONS; NOCICEPTORS; PAIN MEASUREMENT; PERIAQUEDUCTAL GRAY; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTO-ONCOGENE PROTEINS C-FOS; SOMATOSENSORY CORTEX;

ANIMALIA; MUS;

EID: 77956190707     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2010.06.004     Document Type: Article

References (48)

1. Bölcskei K., Helyes Zs., Szabó Á., Sándor K., Petho{double acute} G., Elekes K., Almási R., Pintér E., Szolcsányi J. Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 2005, 117:368-376.
2. Davis-Traber R., Baker S., Lehto S.G., Zhong C., Surowy C.S., Faltynek C.R., Scott V.E., Honore P. Central pituitary adenylate cylase 1 receptors modulate nociceptive behaviours in both inflammation and neuropathic pain states. J. Pain 2008, 9:449-456.
3. Dickinson T., Fleetwood-Walker S.M. VIP and PACAP: very important in pain?. Trends Pharmacol Sci. 1999, 20:324-329.
4. Dickinson T., Fleetwood-Walker S.M., Mitchell R., Lutz E.M. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 1997, 31:175-185.
5. Dickinson T., Mitchell R., Robberecht P., Fleetwood-Walker S.M. The role of VIP/PACAP receptor subtypes in spinal somatosensory processing in rats with an experimental peripheral mononeuropathy. Neuropharmacology 1999, 38:167-180.
6. Ekblad E. Pharmacological evidence for both neuronal and smooth muscular PAC1 receptors and a VIP-specific receptor in rat colon. Regul. Pept. 1999, 85:87-92.
7. Fahrenkrug J., Hannibal J. Pituitary adenylate cyclase activating polypeptide immunoreactivity in capsaicin-sensitive nerve fibres supplying the rat urinary tract. Neuroscience 1998, 83:1261-1272.
8. Hashimoto H., Shintani N., Tanaka K., Mori W., Hirose M., Matsuda T., Sakaue M., Miyazaki J., Niwa H., Tashiro F., Yamamoto K., Koga K., Tomimoto S., Kunugi A., Suetake S., Baba A. Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc. Natl. Acad. Sci. 2001, 98:13355-13360.
9. Hashimoto H., Shintani H., Baba A. New insights into the central PACAP-ergic system from the phenotypes of PACAP- and PACAP receptor-knockout mice. Ann. N.Y. Acad. Sci. 2006, 1070:75-89.
10. Helyes Zs., Pozsgai G., Börzsei R., Németh J., Bagoly T., Márk L., Pintér E., Tóth G., Elekes K., Szolcsányi J., Reglo{double acute}di D. Inhibitory effect of PACAP-38 on acute neurogenic and non-neurogenic inflammatory processes in the rat. Peptides 2007, 28:1847-1855.
11. Jongsma H., Danielsen N., Sundler F., Kanje M. Alteration of PACAP distribution and PACAP receptor binding in the rat sensory nervous system following sciatic nerve transection. Brain Res. 2000, 853:186-196.
12. Jongsma H., Pettersson L.M., Zhang Y., Reimer M.K., Kanje M., Waldenstrom A., Sundler F., Danielsen N. Markedly reduced chronic nociceptive response in mice lacking the PAC1 receptor. Neuroreport 2001, 12:2215-2219.
13. Laburthe M., Couvineau A., Tan V. Class II G-protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
14. Mabuchi T., Shintani N., Matsumura S., Okuda-Ashitaka E., Hashimoto H., Muratani T., Minami T., Baba A., Ito S. Pituitary adenylate cyclase-activating polypeptide is required for the development of spinal sensitization and induction of neuropathic pain. J. Neurosci. 2004, 24:7283-7291.
15. Macpherson J.L., Xiao B., Kwan K.Y., Dubin A.E., Hwang S., Cravatt B., Corey D.P., Patapoutian A. An ion channel essential for sensing chemical damage. J. Neurosci. 2007, 27:11412-11415.
16. Malmberg A.B., Basbaum A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioural and neuroanatomical correlates. Pain 1998, 76:215-222.
17. Meyer R.A., Ringkamp M., Campbell J.N., Raja S.N. Peripheral mechanisms of cutaneous nociception. Textbook of Pain 2006, 3-33. Elsevier, Amsterdam. S.B. McMahon, M. Koltzenburg (Eds.).
18. Meyer R.A., Campbell J.N. Myelinated nociceptive afferents account for the hyperalgesia that follows a burn to the hand. Science 1981, 213:1527-1529.
19. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M.D., Coy D.H. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 1989, 164:567-574.
20. Moller K., Zhang Y.Z., Hakanson R., Luts A., Sjolund B., Uddman R., Sundler F. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 1993, 57:725-732.
21. Mulder H., Uddman R., Moller K., Zhang Y.Z., Ekblad E., Alumets J., Sundler F. Pituitary adenylate cyclase activating polypeptide expression in sensory neurons. Neuroscience 1994, 63:307-312.
22. Mulder H., Jongsma H., Zhang Y.Z., Gebre-Medhin S., Sundler F., Danielsen N. Pituitary adenylate cyclase activating polypeptide and islet amyloid polypeptide in primary sensory neurons: functional implications from plasticity in expression on nerve injury and inflammation. Mol. Neurobiol. 1999, 19:229-253.
23. Muller J.M., Debaigt C., Coursaud S., Montoni A., Pineau N., Meunier A.C., Janet T. Unconventional binding sites and receptors for VIP and related peptides PACAP and PHI/PHM: an update. Peptides 2007, 28:1655-1666.
24. Narita M., Dun S.L., Dun N.J., Tseng L.F. Hyperalgesia induced by pituitary adenylate cyclase-activating polypeptide in the mouse spinal cord. Eur. J. Pharmacol. 1996, 311:121-126.
25. Németh J., Reglo{double acute}di D., Pozsgai G., Szabó Á., Elekes K., Pintér E., Szolcsányi J., Helyes Zs. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice. Neuroscience 2006, 143:223-230.
26. Ohsawa M., Brailoiu G.C., Shiraki M., Dun N.J., Paul K., Tseng L.F. Modulation of nociceptive transmission by pituitary adenylate cyclase activating polypeptide in the spinal cord of the mouse. Pain 2002, 100:27-34.
27. Onou T., Shimizu T., Sakamoto H., Higashi M., Kanmura Y., Miyata A. Involvement of opioidergic system in supraspinal PACAP analgesia and the tolerance. J. Mol. Neurosci. 2007, 33:339-345.
28. Pettersson L.M., Heine T., Verge V.M., Sundler F., Danielsen N. PACAP mRNA is expressed in rat spinal cord neurons. J. Comp. Neurol. 2004, 471:85-96.
29. Riedel W., Neeck G. Nociception, pain, and antinociception: current concepts. Z. Rheumatol. 2001, 60:404-415.
30. Said S.I. VIP and PACAP in pain and inflammation. Trends. Pharmacol. Sci. 2000, 21:57-69.
31. Sakashita Y., Kurihara D., Uchida T., Tatsuno I., Yamamoto T. Involvement of PACAP receptor in primary afferent fibre-evoked responses of ventral roots in the neonatal rat spinal cord. Br. J. Pharmacol. 2001, 132:1769-1776.
32. Sándor K., Bölcskei K., McDougall J., Schuelert N., Reglodi D., Elekes K., Petho{double acute} G., Pintér E., Szolcsányi J., Helyes Zs. Divergent peripheral effects of pituitary adenylate cyclase-activating polypeptide-38 on nociception in rats and mice. Pain 2009, 141:143-150.
33. Sándor K., Helyes Zs., Gyires K., Szolcsányi J., László J. Static magnetic field-induced anti-nociceptive effect and the involvement of capsaicin-sensitive sensory nerves in this mechanism. Life Sci. 2007, 81:97-102.
34. Seltzer Z., Dubner R., Shir Y. A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 1990, 43:205-218.
35. Shimizu T., Katahira M., Sugawara H., Inoue K., Miyata A. Diverse effects of intrathecal pituitary adenylate cyclase-activating polypeptide on nociceptive transmission in mice spinal cord. Regul. Pept. 2004, 123:117-122.
36. Somogyvári-Vígh A., Reglo{double acute}di D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr. Pharm. Des. 2004, 10:2861-2889.
37. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993, 365:170-175.
38. Taiwo Y.O., Levine J.D. Further confirmation of the role of adenyl cyclase and of cAMP-dependent protein kinase in primary afferent hyperalgesia. Neuroscience 1991, 44:131-135.
39. Tjolsen A., Berge O.G., Hunskaar S., Rosland J.H., Hole K. The formalin test: an evaluation of the method. Pain 1992, 51:5-17.
40. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009, 61:283-357.
41. Weston M.C., Peachell P.T. Regulation of human mast cell and basophil function by cAMP. Gen. Pharmacol. 1998, 31:715-719.
42. Xu X.J., Wiesenfeld-Hallin Z. Intrathecal pituitary adenylate cyclase activating polypeptide facilitates the spinal nociceptive flexor reflex in the rat. Neuroscience 1996, 72:801-804.
43. Yamamoto T., Tatsuno I. Antinociceptive effect of intrathecally administered pituitary adenylate cyclase activating polypeptide (PACAP) on the rat formalin test. Neurosci. Lett. 1995, 184:32-35.
44. Zhang Y., Danielsen N., Sundler F., Mulder H. Pituitary adenylate cyclase-activating peptide is upregulated in sensory neurons by inflammation. Neuroreport 1998, 9:2833-2836.
45. Zhang Y., Malmberg A.B., Sjolund B., Yaksh T.L. The effect of pituitary adenylate cyclase activating peptide (PACAP) on the nociceptive formalin test. Neurosci. Lett. 1996, 207:187-190.
46. Zhang Y., Sjolund B., Moller K., Hakanson R., Sundler F. Pituitary adenylate cyclase activating peptide produces a marked and long-lasting depression of a C-fibre-evoked flexion reflex. Neuroscience 1993, 57:733-737.
47. Zhou C.J., Shioda S., Yada T., Inagaki N., Pleasure S.J., Kikuyama S. PACAP and its receptors exert pleiotropic effects in the nervous system by activating multiple signaling pathways. Curr. Protein. Pept. Sci. 2002, 3:423-439.
48. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.